Trial Profile
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With Steroids
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Prednisolone
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MEMBRAINS
- 12 Jul 2023 Planned End Date changed from 6 Jun 2025 to 6 Jun 2028.
- 12 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 16 Sep 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.